

- Discussions with leaders:** Johannes Czernin, MD, talks with Hong Wu, MD, PhD, professor and dean of the School of Life Sciences and a senior investigator of the Peking–Tsinghua Center for Life Sciences at Peking University. **Page 293**
- FAPI review:** Hicks and colleagues look at the development of and preliminary clinical data on various fibroblast-activation protein-specific small-molecule inhibitor tracers in oncologic and potential nononcologic applications. **Page 296**
- Phantom preparation:** Lodge emphasizes the importance of reliable phantom preparation in PET methodology research, performance assessment, and routine quality assurance and describes an existing dilution technique that can simplify the process. **Page 303**
- Nuclear medicine in hyperthyroidism:** Mariani and colleagues provide the first in a series on the role of nuclear medicine in clinical management of benign thyroid disorders, which constitute most diseases affecting the thyroid gland. **Page 304**
- Melanoma imaging and therapy:** Miao and Quinn focus on preclinical and clinical advances in melanocortin-1 receptor- and very late antigen-4–targeted radiolabeled peptides and peptide-conjugated C' dots for melanoma imaging and therapy. **Page 313**
- ¹⁸F-FDOPA and MRI in glioma:** Tatekawa and colleagues identify correlations between PET ¹⁸F-FDOPA uptake and physiologic MRI, including relative cerebral blood volume and apparent diffusion coefficient, in gliomas with different molecular subtypes. **Page 319**
- ¹⁸F-FES vs. ¹⁸F-FDG in ILC:** Ulaner and colleagues detail head-to-head comparison of ¹⁸F-FDG and ¹⁸F-FES in PET/CT assessment of patients with metastatic invasive lobular carcinoma. **Page 326**
- MTV segmentation in DLBCL:** Barrington and colleagues evaluate the optimal automated metabolic tumor volume workflow in diffuse large B-cell lymphoma, assess factors influencing the success of segmentation, and report on the discriminatory power of segmentation methods. **Page 332**
- PET criteria in HL relapse:** Kluge and colleagues compare interim PET responses to second- and first-line treatment in classic Hodgkin lymphoma as part of development of response criteria for relapsed or progressive disease. **Page 338**
- Fluorescence-guided surgery in sarcomas:** Steinkamp and colleagues determine the feasibility, safety, and optimal dose of bevacizumab-800CW for fluorescence-guided surgery in soft-tissue sarcoma, including in vivo and ex vivo tumor detection. **Page 342**
- PET/MRI in isolated limb perfusion:** Chodyla and colleagues evaluate and compare the clinical utility of simultaneously obtained quantitative ¹⁸F-FDG PET and diffusion-weighted MRI datasets for predicting histopathologic response of soft-tissue sarcoma to neoadjuvant isolated limb perfusion. **Page 348**
- uPAR PET/MRI in prostate cancer:** Fosbøl and colleagues assess correlations between uptake of the PET ligand ⁶⁸Ga-NOTA-AE105, targeting the urokinase-type plasminogen activator receptor, and Gleason scores in patients undergoing prostate biopsy. **Page 354**
- ^{99m}Tc-PHC-102 in renal cell carcinoma:** Kulterer and colleagues describe the targeting performance of this radiolabeled derivative of acetazolamide in SPECT imaging in patients with renal cell carcinoma, including safety and tolerability data. **Page 360**
- Immuno-PET and response to therapy:** Pereira and colleagues investigate the utility of receptor tyrosine kinase–targeted immuno-PET to annotate changes in multi-RTK tumor cell expression levels in response to targeted therapies. **Page 366**
- Imaging lymphoma with F(ab')₂ fragments:** Kang and colleagues report on development of ⁶⁴Cu-labeled F(ab')₂ fragments of obinutuzumab for imaging CD20 in lymphoma xenograft tumor models. **Page 372**
- DNA damage in ¹⁷⁷Lu therapy:** Ritt and colleagues compare excess radiation-induced foci and other factors side by side in recipients of ¹⁷⁷Lu-DOTATOC or ¹⁷⁷Lu-prostate-specific membrane antigen-617 radioligands. **Page 379**
- ¹⁷⁷Lu-DOTA-EB-TATE therapy in NETs:** Liu and colleagues report on the safety and efficacy of multiple cycles of ¹⁷⁷Lu-DOTA-Evans blue-TATE peptide receptor radionuclide therapy (PRRT) at escalating doses in neuroendocrine tumors. **Page 386**
- Preclinical ¹⁷⁷Lu-DOTA-JR11 assessment:** Albrecht and colleagues evaluate peptide-receptor radionuclide therapy with somatostatin receptor agonist ¹⁷⁷Lu-DOTATOC and antagonist ¹⁷⁷Lu-DOTA-JR11 with PET/MRI and SPECT/CT in an orthotopic murine pancreatic neuroendocrine neoplasm model expressing human SSTR2. **Page 393**
- PE imaging in asthma:** Lazarus and colleagues look at the diagnostic performance of pulmonary embolism imaging with ventilation–perfusion scanning or CT pulmonary angiography in patients with a history of asthma. **Page 399**
- Early lung perfusion changes in HIV:** Kohli and colleagues investigate pulmonary perfusion and ventilation using ¹³NN-saline PET/CT imaging in smokers and nonsmokers living with HIV. **Page 405**
- Nondisplaceable binding in TSPO PET:** Laurell and colleagues use a recently developed method for simultaneous estimation of nondisplaceable-binding distribution volume to disentangle its contributions from ligand-specific distribution volume in ¹¹C-PBR28 PET studies. **Page 412**
- ¹¹C-UCB-J SUVR in humans:** Naganawa and colleagues detail simplification of the protocol for this PET tracer through comparison of SUV ratios with model-based nondisplaceable-binding potential to derive optimal imaging time windows in healthy and neuropsychiatric subjects. **Page 418**
- Global radiopharmaceutical availability:** Cutler and colleagues from the Nuclear Medicine Global Initiative report on the results of a survey designed to explore issues affecting international access and availability of radiopharmaceuticals. **Page 422**